reports
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside cha...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 ...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent cor...
MacroGenics Announces Date of First Quarter 2024 Financial Results Con...
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024...
Macrogenics Inc: 1 director
A director at Macrogenics Inc sold after exercising options/sold 51,395 shares at 15.549USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data ...
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data, including safety and preliminary efficacy, by May 31Company plans to provide additional clinical data – including rPFS – in the Fall of 2024 ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, devel...
MacroGenics Provides Update on Corporate Progress and 2023 Financial R...
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADCPreclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and MGC028, to be presented in posters at AACRConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on di...
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2024: TD Cowen’s 44th Annual Health Care Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a Prostate Ca...
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Co...
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March ...
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference (New York). MacroGenics’ President and CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
USB U.S. BANCORP
VNO VORNADO REALTY TRUST
VKTX VIKING THERAPEUTICS
TXN TEXAS INSTRUMENTS INCORPORATED
SMCI SUPER MICRO COMPUTER INC.
RMBS RAMBUS INC.
QCOM QUALCOMM INC
PYPL PAYPAL HOLDINGS INC
PSTG PURE STORAGE INC. CLASS A
PEB PEBBLEBROOK HOTEL TRUST
NVMI NOVA MEASURING INSTRUMENTS LTD
NVDA NVIDIA CORPORATION
MGNX MACROGENICS INC.
FORM FORMFACTOR INC.
FAN FABRINET
FFWM FIRST FOUNDATION
APEI AMERICAN PUBLIC EDUCATION
ALLY ALLY FINANCIAL INC
ACU ACME UNITED CORP.
ELTK ELTEK
BKD BANGKOK DEC-CON
KLAC KLA CORPORATION
PLAB PHOTRONICS INC.
FLXS FLEXSTEEL INDUSTRIES INC.
MRUS MERUS B V
ATGE ADTALEM GLOBAL EDUCATION INC.
AMD ADVANCED MICRO DEVICES INC.
AVGO BROADCOM INC.
DELL DELL TECHNOLOGIES INC CLASS C
BSIG BRIGHTSPHERE INVESTMENT GROUP INC.
ARCH ARCH RESOURCES INC. CLASS A
ORIC ORIC PHARMACEUTICALS
VRT VERTIV HOLDINGS CO (A)
MRVL MARVELL TECHNOLOGY INC
NPCE NEUROPACE INC
EWTX ONTO INNOVATION INC.
IRON EDGEWISE THERAPEUTICS INC
DISC MEDICINE INC
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference: 42nd Annual J.P. Morgan Healthcare Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate overview on Thursday, ...
MacroGenics Provides Update on Corporate Progress and Third Quarter 20...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an updat...
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences: BMO Biopharma Spotlight Series: Oncology Day Date: Wednesday, November 8, 2023 Fireside Chat: 10:30 am ET Location: VirtualStifel 2023 Healthcare Conference Date: Tuesday, Novembe...
MacroGenics Announces Date of Third Quarter 2023 Financial Results Con...
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2023 after the market closes on Monday, November 6, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, November ...
- Jonathan Moreland
STAA STAAR SURGICAL CO.
RRGB RED ROBIN GOURMET BURGERS INC.
OXBR OXBRIDGE RE HOLDINGS
MGNX MACROGENICS INC.
GAIA GAIA INC CL A
DG DOLLAR GENERAL CORPORATION
CTRN CITI TRENDS INC.
COTY COTY INC. CLASS A
CODI COMPASS DIVERSIFIED HOLDINGS
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
ADC AGREE REALTY CORPORATION
CSBR CHAMPIONS ONCOLOGY
ASTI ASCENT SOLAR TECHNOLOGIES
NKE INC.
SLNO NIKE
FNKO INC.
VPLM SOLENO THERAPEUTICS INC
VCNX FUNKO CLASS A
ZM VOIP PAL.COM INC.
IMVT VACCINEX
ENX ZOOM VIDEO COMMUNICATIONS
GLT INC.
PVBC IMMUNOVANT INC
PUBM EATON VANCE NEW YORK MUNICIPAL BOND FUND
PRCH GLATFELTER CORPORATION
IMNM PROVIDENT BANCORP INC
NRGX PUBMATIC
GNSS PORCH GROUP INC (A)
RBLX IMMUNOME
ME PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
DSGN GENASYS INC
MPA ROBLOX
EMO 23ANDME HOLDING CO.
BHVN DESIGN THERAPEUTICS INC
TTOO BLACKROCK MUNIYIELD PENNSYLVANIA FD
AGILITI INC.
CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
BIOHAVEN LTD
T2 BIOSYSTEMS INC.
- Jonathan Moreland
- Jonathan Moreland
VGR VECTOR GROUP LTD.
SWX SOUTHWEST GAS HOLDINGS INC.
SMLR SEMLER SCIENTIFC
SEE SEALED AIR CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
MGNX MACROGENICS INC.
GME GAMESTOP CORP. CLASS A
GABC GERMAN AMERICAN BANCORP
FIVE FIVE BELOW INC.
CNTY CENTURY CASINOS INC.
CDXS CODEXIS
ALDX ALDEYRA THERAPEUTICS
OFIX ORTHOFIX INTERNATIONAL N.V.
VIRT VIRTU FINANCIAL INC. CLASS A
SHW SHERWIN-WILLIAMS COMPANY
CULP CULP INC.
FMC FMC CORPORATION
UEIC UNIVERSAL ELECTRONICS INC.
GHC GRAHAM HOLDINGS CO.
SMMF SUMMIT FINANCIAL GROUP INC.
FLWS 1-800-FLOWERS.COM CL A
BRID BRIDGFORD FOODS CORP.
IOVA IOVANCE BIOTHERAPEUTICS INC
FNKO FUNKO CLASS A
QTRX QUANTERIX CORPORATION
QNTO QUAINT OAK BANCORP INC.
ATXI AVENUE THERAPEUTICS
HURC HURCO COMPANIES
EML THE EASTERN COMPANY
VAPO VAPOTHERM INC
JYNT THE JOINT
ASAN ASANA
PVBC PROVIDENT BANCORP INC
MODV MODIVCARE INC
NRGX PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
AKYA AKOYA BIOSCIENCES INC
TSE TRINSEO PLC
MPA BLACKROCK MUNIYIELD PENNSYLVANIA FD
EMO CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
SOL RENESOLA LTD
GATO SUNSHINE SILVER MINING AND REFINING CORP
- Jonathan Moreland
SEE SEALED AIR CORPORATION
MGNX MACROGENICS INC.
GME GAMESTOP CORP. CLASS A
BECN BEACON ROOFING SUPPLY INC.
ALDX ALDEYRA THERAPEUTICS
SHW SHERWIN-WILLIAMS COMPANY
CULP CULP INC.
FLL FULL HOUSE RESORTS INC.
FLWS
FNKO 1-800-FLOWERS.COM CL A
QTRX FUNKO CLASS A
VAPO QUANTERIX CORPORATION
MODV VAPOTHERM INC
NRGX MODIVCARE INC
AKYA PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
MPA AKOYA BIOSCIENCES INC
EMO BLACKROCK MUNIYIELD PENNSYLVANIA FD
SOL CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
RENESOLA LTD
MacroGenics Announces Achievement of $15 Million Milestone Related to ...
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc. (NASDAQ: GILD), nominated the first of two research programs, leveraging MacroGenics’ DART® and TRIDENT® platforms for generating bispecific antibodies. This nomination grants G...
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences: Citi’s 18th Annual BioPharma Conference (Boston). Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in an ADC/Next Gen Panel Discussion on Wednesday, Septe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.